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SUMMARY
Purpose: To review the efficacy and tolerability of stirip-
entol in the treatment of U.S. children with Dravet syn-
drome.
Methods: U.S. clinicians who had prescribed stiripentol
for two or more children with Dravet syndrome between
March 2005 and 2012 were contacted to request partici-
pation in this retrospective study. Data collected included
overall seizure frequency, frequency of prolonged sei-
zures, and use of rescue medications and emergency
room (ER)/hospital visits in the year preceding stiripentol
initiation, and with stiripentol therapy. We separately
assessed efficacy in the following treatment groups: group
A, stiripentol without clobazam or valproate; group B, sti-
ripentol with clobazam but without valproate; group C,
stiripentol with valproate but without clobazam; and
group D, stiripentol with clobazam and valproate. In addi-
tion, adverse effects were recorded.
Key Findings: Thirteen of 16 clinicians contacted for study
participated and provided data on 82 children. Stiripentol
was initiated amedian of 6.0 years after seizure onset and
1.2 years after diagnosis of Dravet syndrome. Compared
to baseline, overall seizure frequency was reduced in 2/6
in group A, 28/35 in group B, 8/14 in group C, and 30/48 in
group D. All children with prolonged seizure frequency
greater than quarterly during the baseline period experi-
enced a reduction in this frequency on the various treat-
ment arms with stiripentol. Similarly, 2/4 patients in
group A, 25/25 in group B, 5/10 in group C, and 26/33 in
group D experienced reduction in frequency of rescue
medication use and 1/1 in group A, 12/12 in group B, 3/5 in
group C, and 18/19 in group D had reduction in frequency
of ER/hospital visits. Adverse effects were reported in 38,
most commonly sedation and reduced appetite. Four
patients (5%) discontinued stiripentol for adverse effects
and two (2%) for lack of efficacy.
Significance: Stiripentol is an effective and well-tolerated
therapy that markedly reduced frequency of prolonged
seizures in Dravet syndrome.
KEY WORDS: Stiripentol, Dravet syndrome, Pediatric
epilepsy, Intractable epilepsy.
Dravet syndrome is a rare, catastrophic childhood epi-
lepsy syndrome that is medically intractable and leads
to intellectual disability, motor impairment, and depen-
dence in adulthood. In most cases, Dravet syndrome
involves a de novo loss of function mutation in the
SCN1A sodium channel gene. The estimated prevalence
is approximately 1/40,900 live births (Brunklaus et al.,
2012), suggesting that 95–100 new cases of Dravet
syndrome will be diagnosed in the United States each
year.
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Antiepileptic drugs are only partially effective for the
treatment of Dravet syndrome–associated seizures (Chiron
& Dulac, 2011). Valproate and benzodiazepines (clobazam,
clonazepam) are the most useful drugs, and open label stud-
ies have suggested that topiramate may also be effective
(Coppola et al., 2002). In addition, both bromides and fen-
fluramine have been reported to be efficacious but are rarely
used, with the latter being unavailable in the United States
(Tanabe et al., 2008; Ceulemans et al., 2012). By contrast,
carbamazepine and lamotrigine often exacerbate epilepsy
and should generally be avoided. The ketogenic diet may
also be effective, with two thirds to three fourths of children
achieving a >75% reduction in seizure frequency (Kang
et al., 2005; Caraballo, 2011; Nabbout et al., 2011).
The efficacy of stiripentol in Dravet syndrome was ini-
tially confirmed in two small, randomized, placebo-con-
trolled studies conducted in France and Italy (Chiron et al.,
2000). Remarkable efficacy was noted when stiripentol was
combined with valproate and clobazam, with approximately
30% of children on stiripentol versus none on placebo
achieving freedom from generalized clonic or tonic–clonic
seizures. In addition, in a study where patients were treated
open-label with stiripentol for a median of 2.9 years, there
was a significant and sustained reduction of seizure fre-
quency and duration compared to baseline (Thanh et al.,
2002). A multicenter study from Japan (Inoue et al., 2009)
also provided additional evidence of unique efficacy in this
medically intractable syndrome.
Because seizures can contribute to intellectual disability,
and status epilepticus can result in numerous hospitaliza-
tions and death, stiripentol use may improve quality of life
and long-term seizure and cognitive outcomes, decrease the
number of emergency room (ER) visits, and possibly pro-
long survival for these children.
Stiripentol is registered as an orphan drug in Europe, Can-
ada, and Japan. It is structurally unrelated to any currently
marked antiepileptic agents, and it acts as an allosteric mod-
ulator of the c-aminobutyric acid (GABA)A receptor
(Fisher, 2009). It displays anticonvulsant properties in a
model of benzodiazepine-refractory status epilepticus in
rodents (Grosenbaugh & Mott, 2013). In addition, stiripen-
tol inhibits the cytochrome P450 (CYP) system, resulting in
increased concentrations of many antiepileptic drugs, most
notably clobazam, by action on CYP2C19 (Tran et al.,
1997).
Although not currently licensed in the United States, it
may be obtained through special access, and some U.S.
patients have received this therapy. However, given that the
costs of non–U.S. Food and Drug Administration (FDA)–
approved drugs are generally not covered by insurers and
that many neurologists will not prescribe a non–FDA-
approved drug, most U.S. children with Dravet syndrome
are unable to access this therapy. The present study was
designed as a retrospective, multicenter survey of children
with Dravet syndrome, treated with stiripentol at various
U.S. centers in order to evaluate the patterns of use of stirip-
entol, and under those conditions, its efficacy, side effects,
and the nature of concurrent medications used.
Methods
Patient identification
Orders for stiripentol from the United States received at
Biocodex, marketing authorization holder for stiripentol,
were reviewed and physicians who treated two or more chil-
dren were contacted. The study goals and design were
reviewed with each physician, and they were then invited to
participate in this retrospective, noninterventional survey.
Participating physicians were requested to provide data for
all children clinically diagnosed with Dravet syndrome who
were treated with stiripentol anytime in the 3 years prior to
study onset.
Data collected
Each participating physician entered clinical data from
their patient’s charts onto standardized data collection forms
in an anonymous manner. Information collected included
demographic data (sex, age at seizure onset, and diagnosis
of Dravet), presence of SCN1Amutation, neurologic exami-
nation findings, and developmental status both prior to sti-
ripentol initiation and at last follow-up. Developmental
status was defined as normal/borderline if the estimated or
measured developmental quotient was 70 or higher, mildly
delayed if 50 to <70, and moderately to severely delayed if
<50.
Epilepsy details prior to stiripentol use and after its initia-
tion including frequency of convulsive, absence, myoclonic
and total seizures, prolonged seizures (defined as duration
>15 min), rescue medication use (rectal diazepam, buccal
diazepam or lorazepam, nasal midazolam or oral clonaze-
pam), and emergency room visits or hospitalizations were
collected. Overall seizure frequency was stratified into the
following categories: (1) daily or more, (2) less than daily to
weekly, (3) less than weekly to monthly, and (4) less than
monthly to yearly. The frequency of convulsive seizures
was stratified into the following: (1) greater than weekly,
(2) less than or equal to weekly to monthly, (3) less than or
equal to monthly to yearly, and (4) less than yearly or less.
The frequency of prolonged seizures, rescue medication
use, and emergency room/hospital visits were stratified into
the following: (1) weekly or more, (2) less than weekly to
monthly, (3) less than monthly to quarterly, and (4) less than
quarterly.
Medical charts were reviewed to determine which of the
following combinations each study participant had been
treated with: (1) stiripentol without concurrent valproate or
clobazam, (2) stiripentol with clobazam but without
valproate, (3) stiripentol with valproate but without cloba-
zam, and/or (4) stiripentol with concurrent clobazam and
valproate. The majority of subjects received only 1–3 of
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these combinations. For each specific combination
received by each participant, age at treatment and duration
of treatment, overall seizure frequency and frequency of
convulsive seizures, prolonged seizures, and rescue medi-
cation use on that combination was noted. No information
about plasma levels was collected.
Data on other prophylactic antiepileptic drugs tried (not-
ing reasons for discontinuation), use of dietary options (tra-
ditional ketogenic diet, modified Atkins diet, low glycemic
index diet), vagus nerve stimulation, and epilepsy surgery
were collected, and timing of each therapy relevant to stirip-
entol was noted.
In addition, adverse effects that occurred on stiripentol
were recorded and the treating physician was asked to grade
their perceived change in the child and family’s quality of
life with the addition of stiripentol (divided into marked
improvement, mild improvement, no change, mild deterio-
ration, and marked deterioration). These standardized forms
were then returned to Biocodex for data entry and analysis.
Data analysis
Efficacy of stiripentol in various combinations
The frequencies of generalized convulsive, absence,
myoclonic and total seizures, as well as prolonged seizures,
use of rescue medication, and emergency room/hospital vis-
its during the one year period prior to starting stiripentol
(baseline period) were compared to each of the following
treatment arms with stiripentol that the child received
[(1) stiripentol without concurrent valproate or clobazam,
(2) stiripentol with clobazam, no valproate, (3) stiripentol
with valproate, no clobazam or (4) stiripentol with concur-
rent clobazam and valproate)]. Although clobazam and
valproate were given a prominent role, as they are the
most commonly used cotherapies with stiripentol, all other
concurrently used antiepileptic medications were duly
noted.
When assessing efficacy of each treatment arm, duration
of therapy was considered. The proportion of children who
had reduction (marked and mild) and increases (marked and
mild) of overall seizure frequency, absence or myoclonic
seizure frequency, prolonged seizures, use of rescue medi-
cation, and emergency room/hospital visits was also deter-
mined. Reduction in frequency of the various outcomes
could be assessed only if a subject’s treatment duration was
longer than their baseline frequency. For example, overall
seizure frequency reduction in a subject with a baseline fre-
quency of less than weekly to monthly could be determined
only if they were treated with the therapy for >1 month.
Similarly, reduction in frequency of rescue medication in a
patient with a baseline frequency of less than monthly to
quarterly could be assessed only if they were treated for
longer than 3 months. Marked reduction was defined as a
decrease in frequency by at least two levels: “daily or more”
to “at least less than weekly,” “weekly or more” to “at least
less than monthly,” or “less than weekly to monthly” to “less
than quarterly.”Mild reduction was defined as a decrease in
frequency of one level: “daily or more” to “at least less than
daily to weekly” or “weekly or more” to “at least less than
weekly to monthly,” or “less than monthly to quarterly” to
“less than quarterly.” Marked increase was defined as a rise
in frequency of at least two levels and mild increase was
defined as a rise in frequency of one level.
Tolerability of stiripentol
Side effects were classified as minor if they did not result
in discontinuation of stiripentol, and major if stiripentol was
stopped as a result. The proportion of children developing
mild and severe side effects, and the nature of side effects
was reported.
All participating sites received approval from their
respective institutional review boards.
Results
Among the 16 physicians contacted who had prescribed
stiripentol for Dravet syndrome in the preceding 3 years, 13
agreed to participate in the study. One physician did not
respond to requests to join the study, one had relocated and
no longer had access to medical records of stiripentol-trea-
ted patients, and the third was unable to get institutional
review board approval for the study within the specified
time limit. In total, 82 children with Dravet syndrome who
received stiripentol through the special access program
between March 2005 and 2012 were identified. The median
number of subjects treated by participating physicians was 4
(25th percentile and 75th percentile, 2 and 10).
Demographic and clinical data are shown in Table 1. Sti-
ripentol was initiated after a median of 6.0 years (25th per-
centile and 75th percentile, 3.8 and 9.3) following seizure
onset and 1.2 years (25th percentile and 75th percentile, 0.3
and 2.9) after diagnosis of Dravet syndrome.
At final follow-up, 44 children (54%) were rated as hav-
ing moderate to severe delay, 31 (38%) as mild delay, and 6
(7%) as normal/borderline (data was missing for one
patient). Regarding ambulation, 73 (89%) were independent
ambulators without aides, 4 (5%) were independent ambula-
tors with aides, and 5 (6%) were nonambulatory. Fifty-six
(68%) were reported to have behavioral problems.
Efficacy of stiripentol
Table 2 shows the number of subjects treated with each
antiepileptic drug treatment arm, the median age at onset
and duration of each treatment, and the frequency of
generalized tonic–clonic seizures, all seizures, prolonged
seizures, rescue medication use, and emergency room
visits/hospitalizations for children prior to and after initia-
tion of stiripentol. Only a small number of children were
treated with stiripentol without concurrent clobazam and/or
valproate, thereby limiting analysis in this subgroup. In
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addition, the median duration of treatment with stiripentol
with valproate but without clobazam was only 3.1 months.
Compared to the baseline period, most children who
received stiripentol in the various treatment arms showed
reductions in overall seizure frequency and in frequency of
both use of rescue medications and emergency room/hospi-
tal visits.
Table 3 shows the change from baseline period in overall
seizure frequency, as well as prolonged seizures, frequency
of rescue medication use, and frequency of emergency
room/hospital visits.
Stiripentol without clobazam or valproate
Six children were treated with stiripentol without concur-
rent clobazam or valproate, and median treatment duration
was 6.3 months (25th and 75th percentile, 3.1 and 8.0).
Children received a median of two other antiepileptic drugs
during this time (25th and 75th percentile, 1 and 3), consist-
ing of clonazepam (3/6), topiramate (3/6), levetiracetam
(2/6), felbamate (1/6), primidone 1/6), and tiagabine (1/6).
Although the numbers are small, overall seizure fre-
quency with stiripentol was reduced in two, unchanged in
three, and increased in one compared to the baseline period.
Both prolonged seizure frequency and emergency room/
hospital visit frequency were markedly reduced in the only
patient experiencing them at least quarterly during the base-
line period. Of the four patients using rescue medication
more than quarterly during the baseline period, two showed
reduction in use (one marked, one mild), one increased use
(mild), and in one child use was unchanged. Conversely,
one child with prolonged seizure frequency less than quar-
terly during the baseline period experienced a marked
increase to less than weekly to monthly with stiripentol.
However, no patient with frequency of rescue medication
use or emergency room/hospital visits less than quarterly
had worsening in these parameters with stiripentol.
None of three children who had absences more than
monthly during the baseline period experienced significant
change in that frequency. Of three children with myoclonic
seizures greater than monthly at baseline, only one showed
mild improvement and in two myoclonic frequency was
unchanged.
Stiripentol with clobazam but without valproate
Thirty-five children received stiripentol with clobazam
but without concurrent valproate for a median treatment
duration of 21.8 months (25th and 75th percentile, 9.5 and
43.9). Children received a median of one other antiepileptic
drug during this time (25th and 75th percentile, 1 and 2)
consisting of topiramate (19/35), levetiracetam (7/35), fel-
bamate (5/35), ethosuximide (4/35), zonisamide (3/35),
phenobarbital (3/35), clonazepam (2/35), lamotrigine
(2/35), methsuximide (1/35), and steroids (1/35). In addi-
tion, one child received nutritional supplements and another
received verapamil.
Compared to the baseline period, overall seizure fre-
quency was reduced in 28 (80%) (markedly in 11 and
mildly in 17), unchanged in 7 (20%), and increased in
none. Frequencies of prolonged seizures, rescue medica-
tion use and emergency room/hospital visits were reduced
Table 1. Demographic and clinical data
Variable
Sex (male) 38 (46%)
Median age at first seizure 6.0 months (25th and 75th percentile, 4.0 and 8.0)
Median age at diagnosis of Dravet syndrome 5.4 years (25th and 75th percentile, 2.4 and 8.8)
Median age at stiripentol initiation 6.9 years (25th and 75th percentile, 4.2 and 10.4)
Duration of stiripentol therapy in months
Median (25th and 75th percentile ) 22.3 months (9.9 and 43.2)
Mean (standard deviation) 28.5 (20.3)
SCN1Amutation present 90.2%
Median number of antiepileptic drugs tried prior to stiripentol initiation 7.0 (25th and 75th percentile, 6.0 and 9.0)
Number with vagus nerve stimulator placed prior to stiripentol 21 (25.6%)
Number treated with dietary therapy (ketogenic diet, modified Atkins diet,
low glycemic diet) prior to stiripentol
46 (56.1%)
Number undergoing epilepsy surgery prior to stiripentol 6 (7.3%)
Developmental status prior to stiripentola (%)
Normal/borderline delay 11 (13.6)
Mild delay 24 (29.6)
Moderate/severe delay 46 (57.0)
Median initial target dose of stiripentol in mg/kg/day 28 (25th and 75th percentile, 20 and 43)
Median maximal dose of stiripentol over treatment course in mg/kg/day 42 (25th and 75th percentile, 30 and 56)
Median stiripentol dose at last follow-up in mg/kg/day 30 (25th and 75th percentile, 22 and 43)
(N = 82). a1 Unknown.
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in all children who had experienced these outcomes at least
quarterly during the baseline period, and the degree of
reduction was marked in 82%, 52%, and 83% of cases,
respectively. One of 22 children who had prolonged sei-
zures less than quarterly and another 1/22 who had emer-
gency room/hospital visits less than quarterly during the
baseline period experienced a mild increase with stiripen-
tol/clobazam to less than monthly to quarterly. In addition,
one of eight children using rescue medication less than
quarterly during the baseline period experienced a mild
increase in use to less than monthly to quarterly after stirip-
entol/clobazam was added.
Of 14 with absence seizures more than monthly during
baseline, 10 showed reduction (five marked and five mild),
whereas four had no change in frequency. Of 11 with myo-
clonic seizures greater than monthly at baseline, eight
showed reduction (five marked and three mild), and in three
frequency was unchanged.
Stiripentol with valproate but without clobazam
Fifteen children received stiripentol and valproate with-
out concurrent clobazam for a median duration of
3.1 months (25th and 75th percentile, 0.9 and 12.8). Chil-
dren received a median of one other antiepileptic drug dur-
ing this time (25th and 75th percentile, 1 and 2) including
clonazepam (6/15), topiramate (4/15), clorazepate (4/15),
levetiracetam (4/15), ethosuximide (2/15), zonisamide (2/
15), phenobarbital (1/15), lorazepam (1/15), and acetazola-
mide (1/15).
Overall seizure frequency was reduced in 8/14 (57%)
(four marked and four mild), unchanged in 6 (43%), and
increased in none compared to the baseline period. Pro-
longed seizure frequency was reduced in all children (80%
markedly) experiencing these at least quarterly during the
baseline period. Frequency of rescue medication use was
reduced in 5 (50%), unchanged in 3 (30%), and increased in
2 (20%) of those with at least quarterly use during the
Table 2. Seizure frequency prior to and after initiation of stiripentol
Year prior to
stiripentol
initiation
Stiripentol
without
valproate or
clobazam
Stiripentol with
clobazam but
without
valproate
Stiripentol with
valproate but
without
clobazam
Stiripentol with
clobazam and
valproate
Number of patients treated 82 6 35 15 48
Median age at treatment onset in months 6.9 (age at
STP initiation)
6.1 6.1 5.4 8.6
Median duration of treatment in months
(25th and 75th percentile)
12 (12, 12) 6.3 (3.1, 8.0) 21.8 (9.5, 43.9) 3.1 (0.9, 12.8) 20.7 (10.5, 35.5)
Frequency of generalized convulsive seizures (%)
Yearly or less 7 (9) 2 (33) 10 (29) 3 (20) 18 (37)
≤Monthly to >yearly 10 (12) 1 (17) 8 (23) 4 (27) 8 (17)
≤Weekly to >monthly 27 (33) 1 (17) 13 (37) 7 (47) 12 (25)
>Weekly 38 (46) 2 (33) 4 (11) 1 (7) 10 (21)
Frequency of all seizures combined (%)
<Monthly to yearly 0 0 10 (29) 2 (13) 17 (35)
<Weekly to monthly 18 (22) 2 (33) 16 (46) 6 (40) 9 (19)
<Daily to weekly 23 (28) 3 (50) 6 (17) 4 (27) 11 (23)
Daily or more 41 (50) 1 (17) 3 (9) 3 (20) 11 (23)
Frequency of prolonged seizures (%) 3 data missing 1 data missing
<Quarterly 51 (65) 5 (83) 32 (94) 9 (60) 45 (94)
<Monthly to quarterly 6 (8) 0 2 (6) 2 (13) 1 (2)
<Weekly to monthly 16 (20) 1 (17) 0 4 (27) 0
Weekly or more 6 (8) 0 0 0 2 (4)
Status epilepticus (≥30 min)
Yes (N, %) 44 (54) 0 (0) 1 (3) 3 (20) 5 (10)
Mean duration of longest status in minutes 186 60 105 201
Frequency of rescue medication use (%) 5 data missing
<Quarterly 17 (22) 2 (33) 23 (66) 3 (20) 33 (69)
<Monthly to quarterly 16 (21) 2 (33) 6 (17) 2 (13) 4 (8)
<Weekly to monthly 23 (30) 2 (33) 6 (17) 9 (60) 5 (10)
Weekly or more 21 (27) 0 0 1 (7) 6 (13)
Frequency of ER visits or hospitalizations (%) 3 data missing 1 data missing 2 data missing
<Quarterly 51 (65) 6 (100) 32 (94) 7 (47) 42 (91)
<Monthly to quarterly 20 (25) 0 2 (6) 4 (27) 3 (7)
<Weekly to monthly 6 (8) 0 0 3 (20) 0
Weekly or more 2 (3) 0 0 1 (7) 1 (2)
STP, stiripentol.
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baseline period. The frequency of emergency room/hospital
visits was reduced in 3 (60%) and unchanged in 2 (40%) of
those with visits at least quarterly during the baseline period.
No child who had prolonged seizures, rescue medication
use, or emergency room/hospital visits less than quarterly
during the baseline period experienced an increase in these
frequencies with stiripentol/valproate therapy.
Of seven children with absence seizures more than
monthly at baseline, two showed reduction (one marked and
one mild) and frequency was unchanged in the remaining
five. Of 10 with myoclonic seizures greater than monthly at
baseline, 7 showed reduction (3 marked and 4 mild) and fre-
quency was unchanged in the remaining 3.
Stiripentol with concurrent clobazam and valproate
Forty-eight children received stiripentol with con-
current valproate and clobazam for a median duration of
20.7 months (25th and 75th percentile, 10.5 and 35.5).
Table 3. Change frombaseline in overall seizure frequency and in those having prolonged seizures, use of rescue
medication or ER/hospital admission at least quarterly
Overall seizure
frequency
N (%)
Prolonged seizure
frequency
N (%)
Frequency of rescue
medication use
N (%)
Frequency of ER
visits or hospitalizations
N (%)
STP without clobazam or valproate
N 6 1 4 1
Reduction 2 (33) 1 (100) 2 (33) 1 (100)
Marked 0 1 (100) 1 (17) 1 (100)
Mild 2 (33) 0 1 (17) 0
Unchanged 3 (50) 0 1 (17) 0
Increase 1 (17) 0 1 (17) 0
Marked 0 0 0 0
Mild 1 (17) 0 1 (17) 0
STP plus clobazam
N 35 11a 25b 12c
Reduction 28 (80) 11 (100) 25 (100) 12 (100)
Marked 11 (31) 9 (82) 13 (52) 10 (83)
Mild 17 (49) 2 (18) 12 (48) 2 (17)
Unchanged 7 (20) 0 0 0
Increase 0 0 0 0
Marked 0 0 0 0
Mild 0 0 0 0
STP plus valproate
N 14d 5d 10e 5f
Reduction 8 (57) 5 (100) 5 (50) 3 (60)
Marked 4 (29) 4 (80) 1 (10) 2 (40)
Mild 4 (29) 1 (20) 4 (40) 1 (20)
Unchanged 6 (43) 0 3 (30) 2 (40)
Increase 0 0 2 (20) 0
Marked 0 0 0 0
Mild 0 0 2 (20) 0
STP plus clobazam and valproate
N 48 18a 33g 19h
Reduction 30 (63) 18 (100) 26 (79) 18 (95)
Marked 17 (35) 16 (89) 16 (48) 11 (58)
Mild 13 (27) 2 (11) 10 (30) 7 (37)
Unchanged 16 (33) 0 4 (12) 1 (5)
Increase 2 (4) 0 3 (9) 0
Marked 0 0 1 (3) 0
Mild 2 (4) 0 2 (6) 0
STP, stiripentol.
aExcluded two subjects with unknown frequency of prolonged seizures prior to stiripentol.
bExcluded one subject whose treatment duration was too brief to assess response and another with unknown frequency of rescue medication use prior to sti-
ripentol.
cExcluded one subject whose frequency of ER/hospital visits prior to stiripentol was unknown.
dExcluded one subject whose treatment duration was too brief to assess response.
eExcluded four subjects whose treatment duration was too brief to assess response and another with unknown frequency of rescue medication use prior to sti-
ripentol.
fExcluded two subjects whose treatment duration was too brief to assess response.
gExcluded two subjects whose treatment duration was too brief to assess response and another three with unknown frequency of rescue medication use prior
to stiripentol.
hExcluded three subjects whose frequency of ER/hospital visits prior to stiripentol was unknown.
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Children received a median of 1 other antiepileptic drug
during this time (25th and 75th percentile, 0 and 2), which
consisted of topiramate (14/48), levetiracetam (9/48), eth-
osuximide (3/48), clonazepam (2/48), clorazepate (2/48),
phenobarbital (2/48), phenytoin (2/48), lamotrigine (2/48),
felbamate (1/48), vigabatrin (1/48), zonisamide (1/48), lo-
razepam (1/48), methsuximide (1/48), and intravenous gam-
maglobulin (1/48). One child also received verapamil.
Overall seizure frequency was reduced in 30 (63%) (17
marked and 13 mild), unchanged in 16 (33%), and increased
in 2 (4%) (both mild) compared to the baseline period. Pro-
longed seizure frequency was reduced in all 18 children (16
marked and 2 mild) who had prolonged seizures at least
quarterly during the baseline period. Frequency of rescue
medication use was reduced in 26 (79%), unchanged in 4
(12%), and increased in 3 (9%) (1 marked and 2 mild) of 33
children who used this at least quarterly during the baseline
period. The frequency of emergency room/hospital visits
was reduced in 18/19 (95%) and unchanged in 1 (5%) of
those with visits at least quarterly during the baseline per-
iod. Only 2/28 children with a prolonged seizure frequency
of less than quarterly, 1/10 with rescue medication use less
than quarterly, and 1/26 with emergency room/hospital visit
frequency less than quarterly during the baseline period had
an increase in these frequencies with stiripentol/clobazam/
valproate.
Of 19 with absence seizures more than monthly at base-
line, 13 showed reduction (8 marked and 5 mild), 5 were
unchanged, and 1 had a mild increase in absence frequency.
Of 21 with myoclonic seizures more than monthly at base-
line, 14 showed reduction (7 marked and 7 mild), and 7 had
no change in frequency.
Tolerability
The median maximal dose of stiripentol used in the pres-
ent study was 42 mg/kg/day (25th and 75th percentile, 30
and 56), and the median dose at last follow-up was 30 mg/
kg/day (25th and 75th percentile, 22 and 43).
Adverse effects were reported in 31 patients (38%), being
mild and not requiring stiripentol discontinuation in the
majority. There was no significant difference in maximal
doses of stiripentol in patients with and without adverse
effects (43.5 vs. 46.1 mg/kg/day). Table 4 illustrates which
adverse effects were reported and their frequencies. The
most common adverse effects were sedation and decrease in
appetite. Some episodes of “seizure” or “convulsions” were
reported as adverse events by several investigators. How-
ever, as all subjects had seizures, we considered these as part
of the disease, and reflective of poor efficacy rather than
truly an adverse event. Only four (5%) discontinued stirip-
entol for adverse effects (two reduced appetite/weight loss
and two worsening behavior). In addition, two children
stopped for lack of efficacy and one for financial reasons.
Over the study period, two children (2.4%) died while
taking stiripentol; however, the causes of death were judged
by the prescribing physician to be unrelated to stiripentol.
The annual mortality rate was 1.02%, based on the total
treatment duration of our subjects of 194.75 patient years. A
4-year-old girl, who had been on stiripentol for 4 months,
was found dead the day following a tonsillectomy. No
autopsy was performed. In the second case, a 6-year-old
girl, who had been on stiripentol for 3 years in conjunction
with valproate and clobazam, was found dead in the morn-
ing, face down on a pillow. No seizure had been witnessed
and an autopsy was consistent with sudden unexplained
death in epilepsy, showing an anatomically normal brain
with no other anatomic cause of death discernible.
Based on the treating physician’s impression, patient and
family quality of life was markedly improved in 40 (49%),
somewhat improved in 32 (39%), unchanged in 4 (5%),
mildly deteriorated in 3 (4%), and markedly deteriorated in
3 (4%).
Discussion
The cohort of children in this study had the typical clini-
cal features of Dravet syndrome with severe epilepsy, fre-
quent seizures of varying semiologies, recurrent status
epilepticus which often led to hospital admission, and
medical intractability. The majority experienced reduction
Table 4. Adverse effects reported with stiripentol
Number (%) of
patients (N = 82)
Nervous system signs and symptoms 22 (26.8)
Sedation/somnolence 15 (18.3)
Ataxia or balance disorder 4 (4.9)
Seizures/convulsions 3 (3.7)
Drooling 1 (1.2)
Gait apraxia 1 (1.2)
Psychomotor hyperactivity 1 (1.2)
Slow speech 1 (1.2)
Tremor 1 (1.2)
Psychiatric/behavioral signs and symptoms 6 (7.3)
Insomnia 3 (3.7)
Abnormal behavior or aggression 2 (2.4
Depressed mood 1 (1.2)
Stuttering 1 (1.2)
Hallucination, visual 1 (1.2)
General signs and symptoms 8 (9.8)
Fatigue 2 (2.4)
Crying or irritability 2 (2.4)
Pain 1 (1.2)
Weight loss 4 (4.9)
Eye signs and symptoms 1 (1.2)
Scleral icterusa 1 (1.2)
Gastrointestinal signs and symptoms 8 (9.8)
Vomiting 1 (1.2)
Decreased appetite 7 (8.5)
Liver function test abnormal 1 (1.2)
Skin and subcutaneous tissue signs and symptoms 1 (1.2)
Photosensitivity reaction 1 (1.2)
aPatient also had abnormal liver function tests.
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in frequency of prolonged seizures, rescue medication use,
and emergency room/hospital visits with stiripentol. In
addition, most children showed mild or marked reduction in
overall seizure frequency, as well as absence and myoclonic
seizure frequency. This finding is notable, since these
patients had documented intractability, having tried a med-
ian of seven antiepileptic drugs that failed to adequately
control seizures. Over half had also tried dietary therapy
without efficacy, and many failed vagus nerve stimulation
therapy. Notably, stiripentol dose used in this study was
often lower than the recommended dosage of 50 mg/kg/
day.
The efficacy of stiripentol for seizure control in our
cohort is consistent with previous work. In a double-blind,
randomized, placebo-controlled trial of stiripentol added on
to both clobazam and valproate, 71% showed a >50% reduc-
tion in tonic–clonic seizure frequency during the second
month of stiripentol treatment (Chiron et al., 2000). Further
studies have confirmed the unique efficacy of stiripentol in
Dravet syndrome (Thanh et al., 2002; Inoue et al., 2009).
Stiripentol acts by various mechanisms. It significantly
increases the GABAergic postsynaptic currents at clinically
relevant concentrations and in a concentration-dependent
manner, by enhancing the opening duration as opposed to
the opening frequency of the chloride channel (Quilichini
et al., 2006). Stiripentol is a direct allosteric modulator of
the GABAA receptor, with particular affinity for the a3-con-
taining receptors, a type of subunit highly expressed in the
developing brain (Laurie et al., 1992; Fisher, 2009).
In addition, stiripentol is a potent inhibitor of the cyto-
chrome P450 system, with particular inhibition of
CYP2C19 and additional inhibition of CYP1A2, CYP2C9,
and CYP3A4. Stiripentol is most commonly combined with
valproate and clobazam in treating Dravet syndrome, result-
ing in no appreciable change in plasma valproate concentra-
tions but approximately twofold increases in clobazam and
five- to sevenfold increases in norclobazam levels (Giraud
et al., 2006). Therefore, efficacy may result in part from ele-
vated clobazam and norclobazam levels. We found support
for a synergistic effect of stiripentol and clobazam, as sei-
zure control on this combination (with or without valproate)
appeared better than without clobazam cotherapy. However,
although the number of children treated without clobazam
cotherapy was relatively small in this study, our results sug-
gest independent benefit from stiripentol alone. Frequency
of prolonged seizures was reduced, often markedly, and
most patients also had reductions in the use of rescue medi-
cation and emergency room/hospital visits. Our results are
similar to those of the open-label Japanese study, in which
short-term responder rates of 61% were seen, even though
only half of children received clobazam cotherapy (Inoue
et al., 2009).These clinical results are consistent with the
patch-clamp recording findings by Fisher that stiripentol
acts directly on the GABAA receptors at a site distinct from
benzodiazepines, that both stiripentol and clobazam/nor-
clobazam act independently at GABAA receptors, and that
the combination of their effects increases the maximum
response beyond that of either drug alone (Fisher, 2011).
Somewhat surprisingly, we found that children treated
with valproate, clobazam, and stiripentol did not have better
seizure control than those treated with stiripentol and cloba-
zam without valproate. Whether valproate provides further
benefit in subjects already receiving clobazam and stiripen-
tol will need to be evaluated in a prospective study.
Very few subjects were reported to have increased sei-
zures. A mild increase in seizure frequency was reported in
only 1/6 children on stiripentol without clobazam or valpro-
ate, and 2/48 children treated with stiripentol with clobazam
and valproate. Only 2% discontinued stiripentol for lack of
efficacy, which is notable given that a median of seven an-
tiepileptic therapies had previously failed to adequately
control seizures.
Stiripentol was well tolerated. Similar to results of previ-
ous studies, the most common adverse effects were seda-
tion, decreased appetite with poor weight gain, insomnia,
and ataxia. Many adverse effects were effectively managed
by dose reduction of stiripentol and/or comedications. Only
5% discontinued stiripentol due to adverse effects, which
included reduced appetite/weight loss in two and worsening
behavior in two. Two subjects died during stiripentol treat-
ment but deaths were considered unrelated in both cases.
Dravet syndrome carries a significant risk of other comor-
bidities. Similar to our results, Genton et al. (2011) reported
problematic long-term outcomes, with persisting seizures,
cerebellar dysfunction, gait impairment, moderate to severe
intellectual disability, and behavior concerns based on their
series of 24 patients followed into adulthood. Although these
comorbidities are likely not solely the result of poor seizure
control, prevention of prolonged seizures, reduction of over-
all seizure frequency will likely improve long-term outcome
for patients with Dravet syndrome. Furthermore, many of our
subjects also showed reductions in absence and myoclonic
seizures, which have been reported to be associated with
greater risk of cognitive impairment (Ragona, 2011).
Mortality is elevated in Dravet syndrome, with studies
reporting that 7–21% of children die before reaching adult-
hood (Akiyama et al., 2010; Genton et al., 2011; Sakauchi
et al., 2011; Skluzacek et al., 2011). Status epilepticus and
its consequences account for a large number of deaths in
younger patients, and sudden unexplained death in epilepsy
results in deaths at all ages. Based on their data from the
International Dravet Syndrome Epilepsy Action League
patient registry, Skluzacek et al. (2011) reported an annual
mortality rate from sudden unexplained death in epilepsy of
0–1.3% per year (mean 0.6%) and from fatal status epilepti-
cus of 0–1.32% per year (mean 0.37%). In our study, neither
the overall annual mortality rate of 1.02% nor the overall
rate of 2.4% appears excessive.
Despite its efficacy in Dravet syndrome, stiripentol
was used late in the course—only after a median of seven
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antiepileptic medications, and often dietary therapy, vagus
nerve stimulation, and even epilepsy surgery had failed. In
part, this is because of a delayed diagnosis of Dravet syn-
drome, as the median time from first seizure until definitive
diagnosis was 4.8 years. However, even after definitive
diagnosis, initiation of stiripentol was additionally delayed
by a median of 1.2 years, likely the result of difficulty
accessing a medication that is not currently approved for
use in the United States, and the cost barrier for many fami-
lies.
The present study had a number of limitations. Given its
design, the overall seizure frequency, frequency of pro-
longed seizures, rescue medication use, and emergency
room/hospital visits were recorded retrospectively based on
chart review, which is less accurate than prospective counts.
In addition, children were on a varied number and type of
other antiepileptic therapies. We did not formally assess
dose changes in those but presumed that stiripentol was
being added because prior medications had failed to provide
adequate seizure control. Given the prominent pharmaco-
logic interaction with many antiepileptic medications such
as clobazam, doses of these were often reduced when stirip-
entol was added. Although medications such as carbamaze-
pine and lamotrigine have been reported to exacerbate
seizures in Dravet syndrome, only a very small proportion
of our cohort received these, and thus discontinuation of
these medications could not explain the dramatic improve-
ment in seizure control seen in so many of our subjects. The
target dose of stiripentol varied between patients and the
median dose was relatively low, but it still afforded good
seizure control in many children. The subject number in cer-
tain treatment arms (particularly stiripentol without cloba-
zam or valproate) was low, limiting our ability to draw
conclusions on its efficacy. The low number in this sub-
group likely reflects prior work that suggests stiripentol
should be used as a cotherapy with valproate and/or cloba-
zam (Chiron et al., 2000). The duration of treatment in cer-
tain arms (particularly stiripentol with valproate but without
clobazam) was also brief, which likely limited our ability to
document efficacy, particularly in those with low baseline
frequencies. Adverse effects were based on chart review,
which likely limited detection of milder symptoms. Further-
more, levels of comedications were not routinely obtained
or recorded. Given that stiripentol has prominent pharmaco-
kinetic interactions with many antiepileptic drugs, it is diffi-
cult to know whether reported adverse effects were due
primarily to stiripentol or rather to altered concentrations of
another comedication, resulting from addition of stiripentol.
Finally, although we assessed frequency of rescue medica-
tion use, it is known that some families use rescue medica-
tion even for brief seizures. Therefore, reduction in
frequency of use may either reflect decreased frequency of
prolonged seizures, or decreased overall seizure frequency.
Given the present results and those of other studies
(Chiron et al., 2000; Inoue et al., 2009), we believe that
stiripentol should be considered earlier in the therapeutic
armamentarium for Dravet syndrome, particularly if cloba-
zam and valproate have failed to provide adequate seizure
control and before trying topiramate, levetiracetam, eth-
osuximide, and other less proven drugs. This approach will
also reduce exposure to ineffective antiepileptic drugs and
their adverse effects, reduce health care costs for emergency
room visits, hospitalizations, and rescue medication, and
most importantly improve quality of life for children with
Dravet syndrome and their families.
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